Two centuries. Countless innovations. One vision.
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
Takeda to Hold First Quarter FY2021 Earnings Conference Calls
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
SEE ALL NEWS AND RELEASES >
・For Shire news releases, click here
Luck is not a strategy: The world needs to start preparing now for the next pandemic
The COVID-19 Mental Burden on Working Mothers
Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021
Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts
Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2021 Takeda Pharmaceutical Company Limited. All rights reserved.